Eva Cecilie Knudsen

Eva Cecilie Knudsen

Auto-generated profile, based on publicly available information

Eva Cecilie Knudsen

Department of Cardiology, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2011 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
EKEva C Knudsen
Eva C Knudsen
ISIngebjørg Seljeflot
Ingebjørg Seljeflot
MAMichael Abdelnoor
Michael Abdelnoor
JEJan Eritsland
Jan Eritsland
AMArild Mangschau
Arild Mangschau
GAGeir Ø Andersen
Geir Ø Andersen
Patients with acute myocardial infarction and newly detected abnormal glucose regulation have been shown to have a less favourable prognosis compared to patients with normal glucose regulation. The importance and timing of oral glucose tolerance testing (OGTT) in patients with acute myocardial infarction without known diabetes is uncertain. The aim of the present study was to evaluate the impact of abnormal glucose regulation classified by an OGTT in-hospital and at three-month follow-up on clinical outcome in patients with acute ST elevation myocardial infarction (STEMI) without known diabetes.

4 November 2005 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
ASAsako Sato
Asako Sato
LTL. Tarnow
L. Tarnow
FNF.S. Nielsen
F.S. Nielsen
EKE. Knudsen
E. Knudsen
HPH.-H. Parving
H.-H. Parving
Background: Left ventricular hypertrophy (LVH) is an independent risk factor for myocardial ischaemia, cardiac arrhythmia, sudden death, and heart failure, all common findings in patients with type 2 diabetes. Aim: To determine the prevalence of, and risk factors for, LVH in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. Design: Cross-sectional study. Methods: From 1994 to 1998, M-mode echocardiography was performed by one experienced examiner in 262 consecutive, normoalbuminuric Caucasian type 2 diabetic patients, all with blood pressure <160/95 mmHg and not taking antihypertensive medication. Mean ± SD age was 54 ± 10 years, 109 were women, and median known duration of diabetes was 4 (range 1–28) years. Body mass index (BMI) was 28 ± 5 kg/m2, and blood pressure 134 ± 13/79 ± 8 mmHg, all means ± SD. Median urinary albumin excretion rate was 9 (range 2–30) mg/24 h. Results: The prevalence of LVH indexed to height2.7 was 43% (95%CI 38–50%), and was similar in men and women. BMI, HbA1c and log urinary albumin excretion were significantly associated with left ventricular hypertrophy in a logistic regression model, whereas sex, age, known duration of diabetes and blood pressure were not. Similar results were obtained for left ventricular mass index. Discussion: LVH was frequent in our normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. Several potentially modifiable risk factors, such as raised BMI, poor glycaemic control and elevated urinary albumin excretion rate, were associated with LVH.

19 April 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EKEva Cecilie Knudsen
Eva Cecilie Knudsen
ISIngebjørg Seljeflot
Ingebjørg Seljeflot
TATonje Amb Aksnes
Tonje Amb Aksnes
JEJan Eritsland
Jan Eritsland
HAHarald Arnesen
Harald Arnesen
GAGeir Øystein Andersen
Geir Øystein Andersen
Studies have reported an association between low levels of natural immunoglobulin M antibodies against phosphorylcholine(IgM anti-PC) and worse prognosis in patients with coronary artery disease (CAD). The aims of the present study were, in patients with ST-elevation myocardial infarction (STEMI); 1) to compare serum levels of IgM anti-PC measured acutely and after 3 months; 2) to study an association between levels of IgM anti-PC and the severity ofCAD, and; 3) to investigate whether IgM anti-PC levels are associated with long-term clinical outcome. A total of 213 patients without known diabetes (median age 59 years) with a PCI treated STEMI were enrolled. IgM anti-PC was measured in-hospital and after 3 months. Median follow-up time was 6.5 years (all-cause mortality, non-fatal myocardial re-infarction, recurrent ischemia causing hospital admission, heart failure and stroke). The severity of CAD was evaluated by coronary angiograms and patients were classified as having single- or multi-vessel disease and by SYNTAX score (SXscore). IgM anti-PC levels were stable over time when measured acutely and after 3 months. Patients with multi-vessel disease and high SXscore had significantly lower levels of IgM anti-PC in the acute phase of STEMI. Low levels of IgM anti-PC (the 25 percentile) measured acutely were associated with a 2-fold increase in the odds of having multi-vessel disease (adjusted OR 2.28 (95% CI 1.17, 4.44), p = 0.016), but not with high SXscore (Crude OR 2.20 (95% CI 0.96, 5.07), p = 0.06). Fifty-three patients experienced a new clinical event during long-term follow-up. Low levels of IgM anti PC were not associated with worse prognosis, (crude HR 1.54 (0.87–2.76), p = 0.14). STEMI patients with multi-vessel disease or high SXscore had significantly lower levels of IgM anti-PC in the acute phase and low levels were associated with multi-vessel disease, but not with worse clinical outcome during long-term follow-up.